MTOR and tuberous sclerosis: Further, with the increasing use of mTOR inhibitors (mTORi) as disease-modifying therapy, manifestations of TSC beyond the hallmark manifestations of subependymal giant cell astrocytoma, angiomyolipomas, LAM, and epilepsy are increasingly relevant [15–21].